FOXP3 and myeloid sarcoma: Although no differences were observed in nTreg (FoxP3+Helios+CD25hiCD127−), progressive MS patients had less FoxP3 than RRMS patients, which was more pronounced in patients with a higher expanded disability status scale (EDSS) ≥ 3.5 [31].